Background. Management of Graves disease includes antithyroid drugs, 131 I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
GRAVES DISEASE (GD) is the most common cause of hyperthyroidism in the United States. It occurs secondary to the effects of thyroid-stimulating immunoglobulins (TSI) on thyrotropin receptors of thyroid follicular cells. There are an estimated 20-30 cases of GD per 100,000 individuals per year with roughly 3% of women and 0.5% of men developing the disease. [1] [2] [3] The peak incidence of GD is between 30-60 years of age, though it can affect all ages. 3 In children, the incidence peaks during adolescence, and GD accounts for 2.5% of childhood goiters. 4 Binding of TSI to thyrotropin receptors in retro-orbital tissues can lead to Graves orbitopathy (GO). 3, 5 The course of GO appears to be dependent on smoking, the level of thyroid dysfunction, presence of persistently elevated TSI levels, and the type of treatment pursued. 6, 7 Management modalities for GD include antithyroid drugs (ATD) with definitive treatment by 131 I radioactive iodine (RAI) or thyroidectomy. While ATD or operation is preferred over RAI in Europe and Japan, RAI has been the preferred therapy in the United States (US). 1, 2, [8] [9] [10] However, recent guidelines have considered thyroidectomy as a comparable treatment option to RAI with an equivalent, long-term quality of life. 2, 8, 11 In addition, recent publications show that the trend in definitive treatment of GD has become primarily operative in some US institutions serving patients with low socioeconomic status. 3, 12, 13 Controversy has existed in regard to the extent of thyroidectomy that should be performed. Subtotal thyroidectomy had been traditionally preferred over total or near-total thyroidectomy due to concerns of permanent hypothyroidism and possible higher complication rates. 1, 5, 14 Over the past decade, however, total or near-total thyroidectomy gained favor after multiple studies showing no difference between complications and highlighting the recurrence risks and occurrence of hypothyroidism associated with subtotal resections. 1, 8, 14, 15 Many factors are considered by both health care providers and patients in providing recommendations and choosing treatment modality. Factors favoring pursuit of RAI over operation include patients with a previously operated neck and those with comorbidities increasing operative risks. Contraindications to RAI are pregnancy, lactation, and presence of thyroid cancer. 2, 8 In the United States, operation is recommended in those with symptomatic compression, large goiters (>80 g), concern for malignancy, the presence of a large nonfunctioning or hypofunctioning nodule, hyperparathyroidism, women desiring pregnancy within 4-6 months, and moderate to severe, active GO. 8 Given the gradual changes in the national trends of GD management in the last few decades, the purpose of this study was to review and compare the definitive treatments (RAI and thyroidectomy) for GD at the University of Iowa Hospitals and Clinics. We hypothesized that operation is a better definitive treatment over RAI for Graves disease when assessing complications and remission rates.
METHODS
After Institutional Review Board approval, a retrospective chart review was conducted encompassing both pediatric (<18) and adult patients undergoing radioactive iodine (n = 295) and/or thyroidectomy (n = 103) for GD between 2003 through 2015. A surgical database was compiled from endocrine surgeons at 5 University of Iowa Hospitals and Clinics (UIHC), and an RAI database was provided by the Department of Nuclear Medicine at UIHC. Both databases were used to collect demographic, clinical, pathologic, and outcome data.
Limited information regarding ophthalmologic disease (eg, proptosis, exophthalmos) and goiter (eg, "enlarged") was gathered based on providers' physical exam documentation. Verification of GO or goiter with an ophthalmologist or ultrasonography, respectively, could be found in only a small number of patients. Patient symptoms were recorded, and primary indication for operative treatment was gathered from providers' assessment portion of notes. Complications were found through review of operative notes, progress notes, follow-up notes, discharge summaries, and medication review during admission.
In the RAI group, pretreatment and treatment nuclear medicine reports were reviewed, which included 4-and 24-hour % uptake of iodine, imaging interpretation, and RAI administered activities. Rapid turnover (RT) was defined as % uptake of iodine that was higher at 4 hours than at 24 hours. RAI was considered successful if no additional RAI doses, thyroidectomy, or ATD was required at 6 months or longer. RAI was administered via a calculation-based approach incorporating 24-hour % uptake, estimated gland weight (palpation, ultrasonography when available), and target activity/g of thyroid tissue of 100-200 mCi.
In the operative group, patients were included if undergoing thyroidectomy and were excluded if no follow-up information was available. One patient with GD underwent lobectomy alone for a cold nodule and was excluded. Patients referred to UIHC solely for RAI and followed at other institutions were excluded. The operative group included 10 patients from the UIHC RAI group who failed treatment and 5 patients who failed RAI at outside institutions. Statistical calculations were performed using the SPSS software package (SPSS Inc, Chicago, IL).
RESULTS
A final cohort of 103 surgical patients and 295 RAI patients were identified and included for analysis (Table I) . Overall, RAI patients were significantly older than those undergoing thyroidectomy (mean age 39.1 vs 33.14, respectively, P < .001). Adults constituted 82.5% of the operative group, while 17.5% were pediatric patients; in contrast, 90.8% were adults and 9.2% were pediatric patients in the RAI group. A higher proportion of pediatric patients were in the operative group than the RAI group (17.5% vs 9.2%, P = .02). Both operative and RAI groups were predominantly women (83.5% and 72.5%, respectively) and Caucasian (82.5% and 78%). GO was present at time of treatment in 29.7% of surgical patients and 29.6% of RAI patients. The operative group had more women (P = .03) and higher mean body mass index (BMI) than the RAI group (30.1 kg/m 2 vs 27.6 kg/m 2 , P = .01), but there was no significant difference in the presence of GO between the 2 groups. Of those undergoing thyroidectomy, 15 (14.8%) patients had previous RAI. Ten of the 15 were from the UIHC definitive RAI group, while the remaining 5 had previous RAI at other institutions.
The RAI group included 295 patients (268 adults and 27 pediatric patients mean age of 41.7 and 13.4, respectively, Table I ). The RAI group had the presence of goiter in 73% of patients (size not accurately determinable); 48 of these patients (41 adults, 7 pediatric) underwent neck ultrasonography. A higher proportion of GO was present in children than adults though not statistically different (44.4% vs 28.1%, P = .07). The first RAI mean dose was 12.9 (±4.2) mCi in adults and 11.2 (±3.2) mCi in children. The second RAI mean dose was 16.1 (±4.0) mCi. Average cumulative dose for patients undergoing 2 RAI therapies was 30.3 (±10.8) mCi. The first RAI mean dose of adults failing therapy was 14.5 (±7.3) mCi.
Radioactive iodine uptake values were observed at 4 and 24 hours (Table II) in all patients; the 4-hour uptake value was not available for one patient. Mean 4-hour values were 45.2% (±22.7) in adults and 56% (±20.8) in children (combined mean 46.2% ± 22.7), and mean 24-hour values in adults and children were 63.4% (±17.4) and 64.7% (±18.2), respectively (combined 63.6% ± 17.4). RT was determined to occur in 8.8% (26/294) with a trend for it being more common in children (n = 21 [8%] in adults and n = 5 [18.5%] in children, P = .07; Table II) .
After the first RAI ablation, follow-up was available for 97% of patients (n = 285/295; Fig) . Remission after the first RAI dose occurred in 81.4% (n = 232/285; 78.6% of those lost to follow-up are assumed to have failed treatment, worst-case scenario [wcs]). Of patients failing RAI who proceeded to a second RAI therapy (n = 29; 23 adults, 6 children), remission occurred in 75.8% (22/29; 68.7% wcs). Persistent failure occurred in 13.8% Surgery Volume 161, Number 1 (4/29; 24.1% wcs). When including all patients undergoing a second RAI therapy, overall remission rate for RAI was 90.1% (254/282; 86.1% wcs). Of patients who failed the first RAI, the proportion of children who failed compared to adults was not different (n = 7, 26.9% vs n = 46, 17.8% respectively, P = 0.25). The pediatric remission rate for the first RAI dose was 73.1% (70.4% wcs); however, overall remission including a second dose was 100% (92.6 wcs). The adult RAI remission rate after the first dose was 82.2% (79.5% wcs). Of adults failing RAI, half went on to a second RAI therapy. In this subgroup, remission occurred in 80% (69.6% wcs). Remission rate for adults including a second RAI therapy was 89.5% (85.4% wcs). Patients with RT rates were more likely to fail the first RAI treatment compared to patients without RT (58.3% vs 14.9%, P < .05, excluding those lost to follow-up).
A total of 103 (85 adults, 18 children) patients were evaluated in the operative group. The majority of patients underwent total thyroidectomy with a few undergoing near-total thyroidectomy. Common presenting symptoms included palpitations or tachycardia, mood changes (anxiety, irritability, mood swings), ophthalmopathy, weight loss, and tremors (Table III) . For those with previous RAI therapy, the average time from RAI to operation was 3.8 (±6.2) years. Compressive symptoms included dyspnea, dysphagia, and hoarseness. Common indications for operation included failure of antithyroid medication (n = 21), patient preference (n = 19), poor compliance (n = 12), failure of RAI (n = 11), GO (n = 10), and compressive symptoms (n = 8, Table III ). Perioperative cold iodine (predominantly Lugols) was used in 75 patients. Of the 103 cases, nerve monitoring was used intraoperatively in 77 (75%).
Complications were higher in the operative group compared to the RAI group (P < .05). All surgical complications, however, were transient (Table IV) . Surgical complications occurred in 30 adults and 8 children (n = 38, 36.9%). Temporary postoperative hypocalcemia (calcium < 8.0 mg/ dL) occurred in 34 individuals, and there were no cases of permanent hypocalcemia. Ten hypocalcemic patients required IV calcium, while the remaining 24 patients were asymptomatic or only required oral calcium. Four of the 8 children required IV calcium.
Other operative complications included transient recurrent laryngeal paresis (n = 3), neck hematoma (n = 1) requiring reoperation, postoperative thyrotoxicosis (n = 1), and transient compression neuropathy of the right arm (n = 1). All cases of transient laryngeal nerve paresis occurred in patients with nerve monitoring. There was no worsening GO or recurrent GD in the operative patients in contrast to the RAI group. The patient with postoperative thyrotoxicosis was febrile and tachycardic in the recovery room despite being on beta-blockers. IV Decadron was administered followed by a dexamethasone taper on discharge. The patient otherwise recovered well.
Eight complications were present in the RAI group (all adults) and included 3 cases of thyrotoxicosis, 2 cases of transient dysphagia, 2 cases of progressive eye disease requiring escalation of therapy (both smokers), and 1 case of tachycardia immediately after treatment (Table IV) . Based on chart review, a total of 87 patients undergoing RAI were deemed to have thyroid-related eye disease (with severity unknown and disease status often not confirmed by an ophthalmologist). Fourteen patients had disease advanced enough to warrant concurrent steroids. After RAI, 2 patients (2.2%) developed GO progression; 1 of the 2 was not on concurrent steroids at the time of therapy. Of the 4 patients experiencing thyrotoxicosis or tachycardia, 2 (including the patient with tachycardia) were on a beta-blocker. Of these 4 patients, one had been treated for <3 months with ATD with free T4 of 1.24 ng/dL (0.92-1.57 ng/dL) one week prior to RAI; one had been treated for 6 months with ATD with discontinuation one month prior to RAI due to development of severe hypothyroidism (but with no laboratory data available from the time of RAI therapy); one had been treated for 3-6 months with ATD with free T4 3.26 ng/dL one week prior to therapy; one had not received ATD treatment and had a free T4 of 4.03 ng/dL on record several months prior to receiving RAI.
Pathology in those with cold nodules diagnosed preoperatively revealed a 1.2 cm papillary carcinoma (n = 1), 3.9 cm Hurthle cell adenoma (n = 1), 0.6 cm papillary microcarcinoma and multiple Hurthle cell nodules (n = 1), 0.3 cm papillary microcarcinoma and multiple adenomatoid nodules (n = 1), and benign hyperplasia (n = 1). In the remaining 98 patients with other indications for thyroidectomy, 8 had papillary microcarcinoma ranging from 0.1 to 1.1 cm on final pathology. The mean specimen thyroid weight was 59.73 g. Mean weight for those with compressive symptoms was 135.1 g vs 53 g in those with other symptoms only (P = .001).
DISCUSSION
Few studies directly compare the definitive treatments for GD, and agreement regarding the best approach for management continues to be developing. In European countries, ATDs tend to be the primary treatment. Surgery or RAI is reserved for cases of recurrence, adverse effects of ATDs, or failure of ATDs 6,9,10,14 ; however, in the United States, RAI tends to be the preferred treatment with operation referral in the presence of potential or confirmed malignancy, in cases of large goiters causing symptomatic compression, with patient preference, or with RAI failure. 1, 8 Previous studies have shown evidence for progression of GO after RAI, and current ATA guidelines recommend operation or ATD over RAI in moderate or severe cases. 6, 8, 16, 17 This is the first study to evaluate operative and RAI management of GD in both adults and children at a tertiary care institution, and this study is unique compared to other series in its inclusion of RT of iodine data.
Pediatric patients constituted a higher proportion of surgical referrals compared to RAI referrals indicating a potential preference for this modality at our institution. Studies of RAI versus thyroidectomy in pediatric populations have both shown low complication rates and acceptable outcomes for either treatment modalities, though the indications for choosing a modality are not standardized. [18] [19] [20] The low complication rate of the pediatric RAI group in our study supports a study by Rivkees and Dinauer 18 who advocated the use of RAI in pediatric GD patients given its safety and efficacy. 18 Chiapponi et al 19 performed a retrospective, matched case-control study evaluating outcomes of total thyroidectomy between pediatric and adult patients for GD finding comparable complication rates. In their study, the rates of postoperative bleeding were the same between both groups (4.8%), transient laryngeal nerve palsy occurred in 4.8% of children compared to 0% in their adult group (not statistically significant), and a higher occurrence of postoperative, transient hypocalcemia was observed in the pediatric group (29.6% vs 4.8%, P = .093). Similar to the Chiapponi findings, we found a higher proportion of children with transient postoperative hypocalcemia compared to adults, but this did not reach statistical significance (44% vs 30.6%, P = .256). In regard to other complications, the only other pediatric complications that occurred were transient dyspnea due to pain (n = 1) and transient laryngeal nerve paresis (n = 1). Remission was 100% in the thyroidectomy group.
For RAI, Rivkees and Dinauer 18 reported a >95% remission rate in the pediatric population. In comparison, the pediatric RAI remission rate in our study after the first dose was 73.1% (n = 19); however, overall remission after a second dose was 100% in whom follow-up was available. Overall, both treatments have similar outcomes in pediatric patients. Those managed by total thyroidectomy tended to have more transient complications but with greater remission rates. The remission rate for adults was comparable to a recent study by Schneider et al 2 and other studies. [21] [22] [23] Of those failing initial RAI who opted for operative treatment, all were successfully treated.
Our analysis found that the presence of RT was associated with RAI failure, similar to findings by Aktay et al. 24 RT is a markedly hyperthyroid state with extreme rapid production and release of thyroid hormone. This shortens the residency time for RAI in the thyroid, which results in a higher likelihood of failure after a single administration of RAI. This presents as a clinical challenge, as increasing RAI doses would not improve residency time and would contribute to increased whole body radiation dose in the form of circulating radioactive thyroid hormone. As a result, the finding of RT on an initial iodine uptake scan may indicate better resolution of this condition with primary definitive treatment by thyroidectomy rather than RAI.
The complication rate of operation was higher compared to the RAI group (36.9% vs 2.7%). However, all complications were transient, and the majority of complications were due to hypocalcemia with a small number of patients requiring IV calcium. Sundaresh et al 21 performed a systematic review and meta-analysis of therapies for GD and reported complications of total thyroidectomy to include hypocalcemia (32.5% temporary, 2.6% permanent), recurrent laryngeal nerve injury (3.43% temporary, 1.46% permanent), and immediate postoperative bleeding (<1%) among 8 studies. In addition, common RAI complications identified by their analysis included new or worsened GO (15-33%) especially in smokers and radiation thyroiditis (1%). 21 Although limited by the number of patients and nonmatched study design, both the operation and RAI groups in our study had a similar number of patients with GO, and only those undergoing RAI experienced long-term worsening eye disease among those with pre-existing GO. Known risk factors for adverse GO outcome after RAI include smokers, high pretreatment T3 values, active and progressive GO over the preceding 3 months, high pretreatment thyrotropin antibody levels, and hypothyroidism. 8 This study is limited by its retrospective, single institution design with relatively small cohort numbers, especially in the pediatric groups for both operation and RAI data sets thus limiting extensive statistical analysis. In addition, the validation and quantification of either goiter or GO by ultrasonography or ophthalmologist were not often available.
In conclusion, this study provides a broad overview of the experience of a single institution with thyroidectomy and RAI as definitive treatments for GD in both pediatric and adult populations. Primary thyroidectomy was universally successful in achieving prompt and complete remission. Rates of remission for RAI were high in adults and children. Transient complications were greater after thyroidectomy. Only RAI patients with pre-existing GO had progressive eye disease requiring escalation of care (0.7%, less than in previous studies 25 ). Additionally, those with RT may be more effectively managed initially with thyroidectomy, as the failure rate of RAI in this group is higher necessitating additional RAI therapy.
Further investigation into the basis for referral patterns selecting for RAI over operation in those with GD and RT (eg, potential cost differences, convenience, and perceived risks among patients and providers) could help improve guidelines for definitive therapy in this subset of patients. Finally, consistent implementation of classification systems (eg, NOSPECS, VISA, or CAS) for Graves eye disease and thyroid ultrasonography for quantification of gland size could aid in completing future, prospective studies.
Dr Allan Siperstein (Cleveland, OH): Number one, over time, did you find a trend toward more or less surgery at your institution? You span 12 years. Number two, for those patients who received radioactive iodine, is your practice to do ultrasounds prior to iodine ablation to exclude nodular thyroid disease that would then mandate a more surgical course?
Dr Vincent Wu: Over time, in terms of the pediatric population, we have seen more referrals of that group for surgery, but we did not specifically look in terms of that. In terms of whether or not ultrasound is done before RAI, it depends on their uptick and if they identify nodules. Otherwise, part of the way that they calculate the dose is more by palpation rather than ultrasound.
Dr Samuel K. Snyder (Temple, TX): I find that the surgeons generally do not see the patients that have Graves disease even in a consultation format to discuss that option. I do not know if you looked at that. Did the patients that had radioactive iodine, did any of them get a chance to see the surgeon? And vice versa, did patients that saw the surgeon for consultation then elect to have radioactive iodine? I do not know if you broke it down.
Dr Vincent Wu: What I found when we went through the records, the pediatric endocrinologists would make the referrals, and in those with RAI, they would generally stick with RAI unless they had palliative treatment, and if they came to us, if the pediatric endocrinologists thought that they would be better served by surgery, they would just come to us and not see additional complications for RAI.
Dr Dina Elaraj (Chicago, IL): I am very interested in this concept of rapid turnover of iodine and the association with failure of radioactive iodine. Perhaps I missed it in your talk, but were there any factors predictive of that, and perhaps we could counsel those patients that they are at risk for failing their first radioactive iodine treatment and perhaps they should consider surgery for treatment? Dr Vincent Wu: I apologize I was not clear on that. The only way to tell if you have rapid turnover of iodine is if you do a 4-hour percent uptake of the radioactive iodine before 24-hour percent uptake of the radioactive iodine. Currently in the Nuclear Medicine National Guidelines, they do recommend that you do a 24-hour percent uptake, and that the 2-to 4-hour percent uptake is more of an optional thing, but you would not know that unless you did a 4-hour percent uptake, and that is why our Department of Nuclear Medicine does that.
Dr Philip I. Haigh (Los Angeles, CA): So there is no way to tell who is going to have rapid turnover before it is given. Dr Vincent Wu: Right. What happens is they do the 4 hours and the 24 hours, and they see the results. There is no strict protocol in the Nuclear Medicine Guidelines on how to approach those patients. So some attendings will send those patients back to the endocrinologist and try something like low-dose antithyroid drugs to see if that affects outcome of the rapid turnover. We do not know the outcome of that yet.
Dr Bradford K. Mitchell (Lansing, MI): I am also very interested in this rapid turnover concept. Is there any other manipulation that might be done? Would you recommend a higher dose to that group of patients, or addition of antithyroid drugs immediately after their dose to increase the retention? Dr Vincent Wu: Yes, thank you for that question. With increasing the dose, there still is the problem that you still have the rapid turnover of that, and, as a result, you actually have increase in whole blood radiation exposure by either thyroid radioactive iodine, thyroid hormone, or radioactive iodine with protein exposure to the brain. In terms of an antithyroid drug, there is a theory that providing a low dose of antithyroid drug up to before the treatment might decrease the rapid turnover rate. However, we need to have more studies to see whether or not that really affects outcome.
Dr Bradford K. Mitchell (Lansing, MI): A second comment or question. I am very reticent to operate on these patients, and I am impressed that the nerve-injury rate and the hypoparathyroid rates are reported as being significantly higher in this group of patients. I am impressed with your results. I wonder if you could tell us, is there anything that your surgeons are doing differently in these patients to protect the nerve or the parathyroid? Do you leave any remnant to protect the nerves or the blood supply to the parathyroid?
Dr Vincent Wu: We may do a near total thyroidectomy in cases where the dissection was more difficult. One measure we tracked in the analysis was the use of a nerve monitor. In patients undergoing surgery without a nerve monitor, there were no nerve injuries.
Dr Brian D. Saunders (Hershey, PA): This is something we see more of in the pediatric referrals. I am just curious if you could go a little bit deeper into your practice profiles. You mentioned 5 surgeons. Are all the pediatric patients being operated upon by one surgeon? Is that a pediatric surgeon or endocrine surgeon?
Dr Vincent Wu: As far as I understand at the moment, at least 3 of our surgeons are operating on pediatric patients, and they are endocrine surgeons.
